4.9.6.2Vertical
Pharmacovigilance & Safety Services
Firms managing adverse event reporting and drug safety compliance.
Market snapshot
These figures describe Life Sciences Consulting & Advisory (4.9.6), the segment that Pharmacovigilance & Safety Services sits within — not Pharmacovigilance & Safety Services on its own.
FragmentationFragmentedEstimate
Not cleanly Census-coded — the mapped biotech-R&D code (541714, ~$91B) measures research activity, not consulting; life-sciences consulting proper sits within management/technical consulting, so it is not sized here.
Business model & economics
Revenue model
Advisory project and managed-service fees
Key economics
- Recurring revenue
- Moderate
- EBITDA margin
- 18–30%
- Capex intensity
- Low
recurring regulatory and pharmacovigilance work
Characteristics
- Navigates regulatory, safety, and market-access complexity.
- Demand tracks drug-development activity.
- Overlaps clinical-research and commercial-analytics services.
M&A deal context
Deal activityModerate
Who’s acquiring
- Life-sciences-services platforms
- CRO & analytics strategics
- PE-backed advisory roll-ups
What’s driving deals
- Consolidation across development-to-commercialization services.
- Regulatory complexity driving demand.
- Drug-development-activity-driven volume.
Find Pharmacovigilance & Safety Services acquisition targets
Search Acquisera’s index for companies classified under Pharmacovigilance & Safety Services (4.9.6.2) and build a targeted deal pipeline.
Search companies